Interpreting 123I–ioflupane dopamine transporter scans using hybrid scores

被引：14

作者：

Nichols K.J. ^{[1
,2
]}

Chen B. ^{[1
]}

Tomas M.B. ^{[1
,2
]}

Palestro C.J. ^{[1
,2
]}

机构：

[1] Department of Radiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY

[2] Division of Nuclear Medicine and Molecular Imaging, Northwell Health, 270-05 76th Avenue, New Hyde Park, 11040, NY

来源：

European Journal of Hybrid Imaging | / 2卷 / 1期

关键词：

!sup]123[!/sup]I–ioflupane; Brain SPECT; DaT; Dementia with Lewy bodies; Dopamine transporters; Parkinson’s disease;

D O I：

10.1186/s41824-018-0028-0

中图分类号：

学科分类号：

摘要：

Background: Dopamine transporter (DaT) 123I–FP-CIT scans most commonly are interpreted visually. Alternatively, absolute quantitation of radiopharmaceutical uptake may improve scan accuracy. However, neither approach accomodates dependence of striatal uptake on age and gender. We investigated whether demographic indexing of visual and numerical variables improve discrimination of patients with essential tremor (ET), Parkinson’s disease (PD), and dementia with Lewy bodies (DLB). Methods: Data of 132 consecutive patients undergoing DaT SPECT scans were reviewed retrospectively. The clinical impression in the latest neurology note was utilized as the final clinical diagnosis. Caudate and putamen specific binding ratio (PSBR) were computed. 123I calibration phantoms were constructed to enable absolute quantitation of putamen radiopharmaceutical uptake. A single experienced nuclear medicine physician graded visual certainty on a 3-level scale. Demographic indexing normalized metrics to published normal PSBR values. Methods were compared by simultaneous ROC analyses to identify the technique of maximal accuracy. Results: Thirty-four patients (26%) were diagnosed with ET, 85 (64%) with PD, 6 (5%) with multiple system atrophy, and 7 (5%) with DLB. For discriminating DLB from PD, visual analysis was significantly less specific and accurate than the other techniques. However, indexing significantly improved specificity and accuracy of visual scores, such that indexed visual scores were statistically equivalent to all other methods. Indexed PSBR yielded essentially the same results as non-indexed PSBR, for which highest overall test efficacy was achieved. Conclusions: Our results in this small series of patients with DLB suggest that if 123I–FP-CIT visual scores are to be used to discriminate DLB from other neurologic disorders, demographic indexing should be applied. However, best results overall are obtained using quantified parameters, regardless of whether or not demographic indexing is applied to these values. © 2018, The Author(s).

引用

共 29 条

[1]

Andringa G., Drukarch B., Bol J.G.J.M., de Bruin K., Sorman K., Habraken J.B.A., Et al., Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson’s disease, NeuroImage, 26, pp. 1150-1158, (2005)

[2]

Bega D., Gonzalez-Latapi P., Zadikoff C., Spies W., Simuni T., Is there a role for DAT-SPECT imaging in a specialty movement disorders practice?, Neurodegener Dis, 15, pp. 81-86, (2015)

[3]

Benamer T.S., Patterson J., Grosset D.G., Booij J., de Bruin K., van Royen E., Et al., Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group, Mov Disord, 15, pp. 503-510, (2000)

[4]

Bostrom F., Jonsson L., Minthon L., Londos E., Patients with Lewy body dementia use more resources than those with Alzheimer’s disease, Int J Geriatr Psychiatry, 22, pp. 713-719, (2007)

[5]

Bostrom F., Jonsson L., Minthon L., Londos E., Patients with dementia with Lewy bodies have more impaired quality of life than patients with Alzheimer disease, Alzheimer Dis Assoc Disord, 21, pp. 150-154, (2007)

[6]

Cummings J.L., Henchcliffe C., Schaier S., Simuni T., Waxman A., Kemp P., The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration, Brain, 134, pp. 3146-3166, (2011)

[7]

Darcourt J., Booij J., Tatsch K., Varrone A., Vander Borght T., Kapucu O.L., Et al., EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2, Eur J Nucl Med Mol Imaging, 37, pp. 443-450, (2010)

[8]

Djang D.S.W., Janssen M.J.R., Bohnen N., Booij J., Henderson T.A., Herholz K., Et al., SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0, J Nucl Med, 53, pp. 154-163, (2012)

[9]

Fearnley J.M., Lees A.J., Ageing and Parkinson’s disease: Substantia nigra regional selectivity, Brain, 114, pp. 2283-2301, (1991)

[10]

Gerasimou G., Costa D.C., Papanastasiou E., Bostanjiopoulou S., Arnaoutoglou M., Moralidis E., Et al., SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson’s disease?, Ann Nucl Med, 26, pp. 337-344, (2012)

← 1 2 3 →